Arishta Export Market Intelligence: India's 153 Suppliers Shipping to 47 Countries — TransData Nexus 2026

Q: Who are the top arishta exporters from India?

The top arishta exporters from India are: 1. DABUR INDIA LIMITED — $590.0K (41.0% market share); 2. GREENSHIP EXPORTS — $297.0K (20.6% market share); 3. SREE EXPORTS — $51.2K (3.6% market share); 4. MULTANI PHARMACEUTICALS LIMITED — $37.9K (2.6% market share); 5. SANIYA EXPORTS & IMPORTS — $36.7K (2.6% market share). Together they account for 70.3% of India's total arishta export value.

Q: What is the total export value of arishta from India?

The total export value of arishta from India is $1.4M USD, recorded across 3,193 shipment transactions from 153 active exporters to 47 destination countries. The average shipment value is $451.

Q: Which countries import arishta from India?

India exports arishta to 47 countries worldwide. The top importing countries are: NEPAL (43.9% share, $632.7K), UNITED ARAB EMIRATES (18.6% share, $267.7K), GERMANY (13.7% share, $196.6K), OMAN (3.6% share, $51.8K), UNITED STATES (3.3% share, $47.4K). These five markets account for 83.1% of total export value.

Q: What is the HS code for arishta exports from India?

The primary HS code for arishta exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of arishta exports from India?

The average unit price for arishta exports from India is $6.89 USD per unit, with prices ranging from $0.02 to $1969.30 depending on formulation, packaging, and order volume. The total market is valued at $1.4M across 3,193 shipments.

Q: Which ports handle arishta exports from India?

The primary ports for arishta exports from India are COCHIN SEA (INCOK1) (12.9% of shipments), COCHIN SEA (11.7% of shipments), TUTICORIN SEA (7.9% of shipments), TUTICORIN SEA (INTUT1) (7.2% of shipments), CHENNAI SEA (INMAA1) (5.7% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of arishta?

India is one of the world's leading exporters of arishta due to its large base of 153 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports arishta to 47 countries, demonstrating 24% global market coverage.

Q: What certifications do Indian arishta exporters need?

Indian arishta exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import arishta from India?

There are 258 registered buyers importing arishta from India, spread across 47 countries. The repeat buyer rate is 75.6%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top arishta supplier from India?

DABUR INDIA LIMITED is the leading arishta exporter from India with a market share of 41.0% and total export value of $590.0K across 272 shipments. The top 5 suppliers together control 70.3% of total export value.

Suresh Sormare

Arishta

India Pharmaceutical Trade Intelligence

$1.4M153 Suppliers47 CountriesHS 30049011

ExportsIndia → NEPAL43.9%India → UNITED ARAB18.6%

#1 Supplier: DABUR INDIA #1 Buyer: LUNA TRADING

Arishta Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Arishta to the World

Between 2022 and 2026, India exported $1.4M worth of arishta across 3,193 verified shipments to 47 countries — covering 24% of world markets in the Ayurvedic & Herbal Products segment. The largest destination is NEPAL (43.9%). DABUR INDIA LIMITED leads with a 41.0% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Arishta export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Arishta export data snapshot — $1.4M · 153 exporters · 47 countriesTransData Nexus · Indian Customs Data

Top Arishta Exporters from India

153 active exporters · Ranked by export value

View all 153 →

Top Arishta Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	DABUR INDIA LIMITED	$590.0K	272	2	41.0%
2	GREENSHIP EXPORTS

Top Countries Importing Arishta from India

47 destination markets · Ranked by import value

All 47 countries →

Top Countries Importing Arishta from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	NEPAL	$632.7K	43.9%
2	UNITED ARAB EMIRATES	$267.7K	18.6%
3	GERMANY	$196.6K	13.7%
4	OMAN	$51.8K	3.6%
5	UNITED STATES	$47.4K	3.3%
6	CANADA	$31.6K	2.2%
7	BAHRAIN	$31.1K	2.2%
8	MALAYSIA	$27.6K	1.9%
9	SINGAPORE	$26.0K	1.8%
10	SAUDI ARABIA	$24.5K	1.7%

NEPAL is India's largest arishta export destination, absorbing 43.9% of total exports worth $632.7K. The top 5 importing countries — NEPAL, UNITED ARAB EMIRATES, GERMANY, OMAN, UNITED STATES — together account for 83.1% of India's total arishta export value. The remaining 42 destination countries collectively receive the other 16.9%, indicating a focused distribution strategy targeting key markets.

Regulatory Landscape — Arishta

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, "Arishta" (HS Code: 30049011) has not been approved by the U.S. Food and Drug Administration (FDA) under an Abbreviated New Drug Application (ANDA). A search of the FDA's Orange Book, which lists approved drug products, confirms the absence of "Arishta" in its records. Consequently, there are no recent approvals or import alerts associated with this product.

Given that "Arishta" is exported from India to 47 countries, including the United States, by 153 active Indian exporters, it is imperative for these exporters to understand the FDA's regulatory requirements. To legally market "Arishta" in the U.S., an ANDA approval is necessary, demonstrating that the product is bioequivalent to an already approved drug. Additionally, compliance with FDA's Current Good Manufacturing Practices (cGMP) is mandatory to ensure product quality and safety. Non-compliance can result in detention without physical examination (DWPE) under FDA's import alert system, as outlined in the FDA's guidelines on importing human drugs.

2EU & UK Regulatory Framework

In the European Union (EU) and the United Kingdom (UK), medicinal products like "Arishta" require marketing authorization before they can be sold. This process involves a comprehensive evaluation by the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to ensure the product's safety, efficacy, and quality. As of March 2026, there are no records indicating that "Arishta" has received such authorization from either the EMA or MHRA.

Manufacturers aiming to export "Arishta" to the EU or UK must adhere to Good Manufacturing Practice (GMP) standards, which are harmonized across these regions. Compliance with these standards is crucial for obtaining and maintaining marketing authorization. Failure to meet GMP requirements can lead to regulatory actions, including suspension or revocation of the marketing authorization.

3WHO Essential Medicines & Global Standards

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. As of the latest edition, "Arishta" is not included in this list. Furthermore, there is no evidence to suggest that "Arishta" has undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products.

Regarding pharmacopoeial standards, "Arishta" must comply with the specifications outlined in recognized compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is essential for ensuring product quality and facilitating international trade.

4India Regulatory Classification

In India, the Central Drugs Standard Control Organisation (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. The specific classification of "Arishta" (e.g., Schedule H, H1, X, or OTC) determines its prescription status and regulatory requirements. As of March 2026, the exact classification of "Arishta" is not specified in available records.

The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines in India. As of March 2026, there is no indication that "Arishta" is subject to a ceiling price under the Drug Price Control Order (DPCO). For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating smooth export operations.

5Patent & Exclusivity Status

As of March 2026, there is no publicly available information indicating that "Arishta" is protected by active patents or exclusivity rights. This suggests that generic competition is permissible, provided that manufacturers comply with the relevant regulatory requirements in their target markets.

6Recent Industry Developments

In the past 12 months, several developments have impacted the pharmaceutical industry:

1. API Price Fluctuations: In June 2025, the Indian government reported a significant increase in the prices of Active Pharmaceutical Ingredients (APIs) due to supply chain disruptions. This has affected the cost structures of pharmaceutical manufacturers, including those producing "Arishta."

2. Regulatory Policy Changes: In September 2025, the CDSCO introduced new guidelines aimed at streamlining the approval process for generic drugs. These changes are expected to expedite the market entry of products like "Arishta."

3. Export Incentives: In December 2025, the DGFT announced enhanced export incentives for pharmaceutical products under the Merchandise Exports from India Scheme (MEIS). This policy aims to boost the export of Indian pharmaceuticals, including "Arishta," to international markets.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of staying informed to navigate the complexities of international trade effectively.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Arishta

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of traditional medicines like Arishta, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese manufacturers. This dependency exposes the supply chain to significant risks, as any disruption in Chinese production or export policies can lead to shortages and increased costs for Indian manufacturers.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns led to immediate scarcities of essential APIs, causing price surges and production delays in India. Despite government initiatives like the Production Linked Incentive (PLI) scheme launched in October 2024 to bolster domestic API production, India's pharmaceutical sector continues to grapple with challenges such as higher production costs, infrastructure limitations, and regulatory complexities.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters of Arishta from India account for 70.3% of total exports, with DABUR INDIA LIMITED alone contributing 41.0%. This high supplier concentration poses a significant single-source risk; any operational or financial issues faced by these key exporters could disrupt the entire supply chain.

Access Complete Arishta Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 3,193 transactions across 47 markets.

Request Demo View Pricing

Frequently Asked Questions — Arishta Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top arishta exporters from India?

The leading arishta exporters from India are DABUR INDIA LIMITED, GREENSHIP EXPORTS, SREE EXPORTS, and 12 others. DABUR INDIA LIMITED leads with 41.0% market share ($590.0K). The top 5 suppliers together control 70.3% of total export value.

What is the total export value of arishta from India?

The total export value of arishta from India is $1.4M, recorded across 3,193 shipments from 153 active exporters to 47 countries. The average shipment value is $451.

Which countries import arishta from India?

India exports arishta to 47 countries. The top importing countries are NEPAL (43.9%), UNITED ARAB EMIRATES (18.6%), GERMANY (13.7%), OMAN (3.6%), UNITED STATES (3.3%), which together account for 83.1% of total export value.

What is the HS code for arishta exports from India?

The primary HS code for arishta exports from India is 30049011. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Arishta

Arishta

How India Exports Arishta to the World

Top Arishta Exporters from India

Top Countries Importing Arishta from India

Quick Facts

Related Ayurvedic & Herbal Products

Related Analysis

Need Details?

Regulatory Landscape — Arishta

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Arishta

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Arishta Trade Intelligence

Frequently Asked Questions — Arishta Exports from India

Who are the top arishta exporters from India?

What is the total export value of arishta from India?

Which countries import arishta from India?

What is the HS code for arishta exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of arishta exports from India?

Which ports handle arishta exports from India?

Why is India a leading exporter of arishta?

What certifications do Indian arishta exporters need?

How many buyers import arishta from India?

What is the market share of the top arishta exporter from India?

Analysis Methodology